石藥集團(01093.HK)一季度純利跌8.4%至14.78億元 營收同比減少21.9%
格隆匯5月29日丨石藥集團(01093.HK)公佈,截至2025年3月31日止一季度,集錄得收入人民幣70.15億元及公司股東應佔呈報溢利人民幣14.78億元,分別較去年同期減少21.9%及8.4%。撇除按公平值計入損益的金融資產之公平值變動及以股份爲基礎之僱員酬金開支後,公司股東應佔基本溢利爲人民幣14.11億元,較去年同期減少18.2%。
基於公司股東應佔呈報溢利的每股基本盈利爲人民幣12.91分,較去年同期減少5.1%。自2024年4月以來,公司積極於公開市場回購股份,以提升每股盈利及實現公司股東回報最大化。由於用作計算每股盈利之普通股加權平均數有所減少,期內每股基本盈利的同比降幅較本公司股東應佔溢利爲低。
報告期內,成藥業務實現收入人民幣55.00億元(包括授權費收入人民幣7.18億元),較去年同期減少27.3%;原料產品業務銷售收入較去年同期增加14.6%至人民幣10.72億元;功能食品及其他業務銷售收入較去年同期減少8.9%至人民幣4.43億元。
2025年第一季度,研發費用較去年同期增加11.4%至人民幣13.02億元,約佔成藥業務收入23.7%。目前有近90個產品在臨牀試驗的不同階段,其中10個已遞交上市申請,超30個重點產品處於註冊臨牀階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.